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Although very late stent thrombosis (VLST) after drug-eluting stent (DES) implantation remains a major concern, the precise
mechanisms have not been clariﬁed. An association between late acquired incomplete stent apposition (ISA) and VLST of DES
has been suggested by several intravascular ultrasound studies demonstrating very high prevalence of ISA in the setting of VLST.




graphic restenosis and clinical need for repeat revasculariza-
tion procedures [1, 2]. However, concerns have been raised
about the safety of DES, and certain issues remain unsolved.
One of the most important issues raised is stent thrombosis
(ST) [3], a catastrophic, albeit infrequent, complication that
results in abrupt coronary artery closure, which can lead
to myocardial infarction or sudden cardiac death [4]. ST
can occur with either bare-metal stents (BMSs) or DES
[5]. Acute or subacute ST includes the events occurring
either during the index procedure (acute) or within 30 days
(subacute). Late ST (LST) has been deﬁned as occurring
from 30 to 360 days after the procedure. Very late ST
(VLST) has been deﬁned as occurring >1y e a rl a t e r[ 6]. LST
and/or VLST has emerged as a distinct entity overshadowing
the use of DES, and concerns persist as to whether this
phenomenon might jeopardize the long-term outcome after
DES implantation [7]. Furthermore, long-term follow-up
studies revealed that VLST could occur at a rate of 0.1% per
year even in patients with BMS implantation, although the
annual incidence of VLST of BMS was much lower than that
after DES implantation [8]. I describe here the mechanism
of ST, especially LST and VLST of DES, from a pathological
standpoint.
2. Mechanismsof ST inDES
2.1. Delayed Arterial Healing. The pathological ﬁndings
from patients who died of late DES thrombosis have
demonstrated that delayed arterial healing characterized by
incomplete reendothelialization is an important underlying
factor [9]. The pathologic ﬁndings of our study revealed
incomplete reendothelialization and sparse smooth muscle
cell coverage compared with that with BMS implanted for a
similar duration (Figure 1). Although the drugs of DES, such
as sirolimus and paclitaxel, reduce neointimal formation by
impending smooth muscle cell migration and proliferation,
these drugs can also impair the normal healing process of
the endothelial cells in injured arterial wall [10]. Thus, LST
may be more frequently related to incomplete healing and/or
inadequate neointimal coverage.
2.2. Late Acquired Stent Malapposition. Although a corre-
lation has been observed between uncovered DES struts
and LST, in our pathological studies of Japanese patients,
considerable number of cases showed neointimal coverage
with reendothelialization of a great deal of the DES struts,
especially in simple lesions beyond 1 year (Figure 2). Thus,
endoluminal mural thrombus in VLST cases may be present







Figure 1: Continued.Thrombosis 3
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Figure 1: (a) The left panels show angiograms of a stable angina patient who underwent successful stent implantation in the native
left anterior descending coronary artery with SES and the ﬁrst diagonal branch with BMS. More than 11 months after stenting, severe
thrombotic occlusion occurred at the proximal SES site, 1 week after cessation of antiplatelet medication. Despite complete revascularization
by thrombus aspiration, the patient died of multiorgan failure 1 week later. (b) Macroscopically, neointimal coverage of the SES struts
was scarcely visible (∗blood clot formed at agonal stage). In contrast, complete coverage by neointima was observed at the BMS site. (c)
Microscopic observation demonstrated no obvious endothelialized struts at the SES site, even at the portion where a mild proliferative
response of smooth muscle cells was evident. At the luminal surface of these nonendothelialized struts, the remnants of ﬁbrin-rich thrombus
were visible. (d) In the BMS segment, however, relatively large neointimal coverage of stent struts was observed. Furthermore, complete









Figure 2: Histological sections of the SES segments harvested beyond 1 year (upper panels) and 2 years (lower panels) after stenting. Note
complete neointimal coverage composed of smooth muscle cells with obvious reendothelialization.4 Thrombosis
(a) (b)
(c) (d)
Figure 3: Histological sections of the plaque-free regions with SES implantation after 11.5 months. Note remarkable depletion of medial
smooth muscle cells (arrowheads) just underneath the SES struts (∗).
unusual vessel responses to DES, such as late acquired
incomplete stent apposition (ISA). Late ISA is highly preva-
lent in patients with VLST after DES implantation [11].
We have revealed two major representative pathological
features concerning LSA: (1) medial necrosis and (2) peri-
stent contrast staining and aneurysm formation after DES
implantation.
2.2.1.MedialNecrosis. LateISAhasbeenobserv edonfollo w-
up intravascular ultrasound (IVUS) in patients who received
sirolimus-eluting stents (SESs) [12]. Although the precise
mechanism of late ISA has not been clariﬁed, focal positive
vessel remodeling is thought to be a potent candidate. We
have reported an autopsy case showing medial necrosis
at the segment of SES several months after implantation
[13]. It is suggested that cytostatic eﬀects of sirolimus on
neointimal formation could be complicated by these local
cytotoxic eﬀects followed by a decrease in arterial tension,
causing stent malapposition. The IVUS study investigating
ISA portions also showed that late acquired ISA in SES was
mainly present on relatively disease-free sites of the vessel
wall [12]. Interestingly, we observed that medial smooth
muscle cell depletion was present only in the portions where
SESstrutsdirectlycontactedthemedialwalllayers(Figure3).
We can deduce that diﬀusion of sirolimus from SES to the
medial layer might be blocked if atherosclerotic plaques are
positioned between SES struts and the medial layer.
Thus, late ISA by focal positive vessel remodeling caused
by medial necrosis may be responsible for LST and/or VLST
after DES implantation.
2.2.2. Peri-Stent Contrast Staining and Coronary Aneurysm
Formation. Peri-stent contrast staining (PSS) was deﬁned
as contrast staining outside the stent contour extending to
≥20% of stent diameter measured by quantitative coronary
angiography. PSS found within 12 months after SES implan-
tation appeared to be associated with subsequent VLST
[14]. PSS could be regarded as representing an abnormal
vessel wall response to DES. Coronary aneurysm and a
mild form of PSS could be regarded as a continuum of
the vessel wall pathological process at the site of DES
implantation. We have reported the ﬁrst case with VLST
demonstrating serial changes in contrast staining outside
the stent border leading to aneurysm formation as well
as histopathologic evidence of hypersensitivity vasculitis in
the stented segment (Figure 4)[ 15]. Virmani et al. [16]
also demonstrated localized hypersensitivity vasculitis of
the arterial wall within the stented segment in a patient
who died of VLST. These two pathological cases suggest
that chronic inﬂammation and/or hypersensitivity vasculitis
to a polymer (a constituent component of DES) might
be an important underlying mechanism of PSS and coro-
nary aneurysm. Furthermore, these pathological ﬁndings
demonstratedthatinﬂammatorycellsdiﬀuselyinﬁltratedthe






Figure 4: (a) These angiograms demonstrated that the SES stented site showed a tendency toward irregularly shaped coronary ectasia (peri-
stent contrast staining; PSS) and ﬁnally saccular aneurysm formation 2 years after SES implantation, followed by VLST 3 months later. (b)
Pathological examination demonstrated focal strut malapposition with aneurysmal dilatation and partially occlusive mural thrombus. (c)
In addition, extensive inﬂammation, consisting primarily of lymphocytes and eosinophils, with a focal giant cell reaction, was evident
at the stented site. An asteroid body with intense foreign body granulomatous inﬂammation was also visible (arrow). Such localized
hypersensitivity vasculitis existed primarily around the struts and extended to the intima and adjoining media and adventitia.
might result in loss of elastic integrity of the vessel wall
leading to ISA. Thus, resultant inﬂammation alters the
vessel wall structures, causing positive remodeling. Although
relatively mild inﬂammatory changes are recognized as PSS
on coronary angiography, extensive vessel wall destruction
by severe inﬂammation can lead to aneurysm formation in
extreme cases.
2.3. Exaggerated Neoatherosclerosis and Neointimal Disrup-
tion following DES Implantation. Recent studies have identi-
ﬁed immune cells and mediators at work in atheroma, impli-
cating inﬂammatory mechanisms in disease development
[17]. As previously described, in DES-implanted segments,
inﬂammation against the durable polymer of the DES, espe-
cially heavy inﬁltration of macrophages around the struts, is
typical. Furthermore, the remarkable presence of lipid-laden
foamy macrophage inﬁltration within the neointima is usu-
ally evident more than several months after DES implanta-
tion. In addition, we [18] and others [19] have demonstrated
that extracellular lipid, such as cholesterol crystals, accumu-
lates and early necrotic core formation is frequentlyobserved
more than 1 year after DES stenting (Figure 5). Recent
angioscopy studies have also revealed that DES promoted the
formation of atherosclerotic yellow neointima in the stent-
implanted lesion at 10-month follow-up [20]. Furthermore,
even in the BMS-implanted segments, it has been reported
thatheavyinﬁltrationofsuchmacrophagesaroundthestruts
implanted for more than 4 to 5 years was documented. These
lipid-laden macrophages showed collagen-degrading matrix
metalloproteinase immunoreactivity, which can degrade the
neointimal layer (Figure 6)[ 21], followed by disruption
of the stented portion (Figure 7). Recently, we examined6 Thrombosis
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Figure 5: Histological sections from a patient with SES implantation 2 years antemortem. Note early necrotic core formation with
pronounced foamy macrophages and circumferential cholesterol clefts (arrows) around the struts.
(a) (b)
(c)
Figure 6: These foamy macrophages (arrowheads) clearly showed immunoreactivity to CD68, MMP-3, and MMP-9. Positive staining for
these MMPs was also observed in the extracellular space.
thrombectomy specimens from a series of 135 patients
undergoing angiography and thrombectomy for deﬁnite
ST [22]. Fragments of atherosclerotic plaques, including
foamy macrophages, cholesterol crystals, and thin ﬁbrous
caps, were observed more commonly in the extracted
thrombi (under negative pressure) from cases of early ST
and VLST, beyond 3 years, as opposed to LST, and were
similar to what was retrieved in acute coronary syndrome.
These results suggest that disruption of neoatheroscle-
rotic neointima may be an important background for




Figure 7: Micrographs of an aspirated specimen from the VLST site in the DES-implanted segment. Note the intimal disruption and
adherent thrombus. Numerous macrophages and cholesterol clefts (arrows) were also visible in both the neointima and the thrombus.
Thus, DES can induce atherosclerotic and thrombogenic
lesions with a signiﬁcantly higher incidence and earlier than
with BMS.
3. Conclusion
LST may be more frequently related to incomplete heal-
ing and/or inadequate neointimal coverage with poor re-
endothelialization. However, in the cases of VLST, several
pathological studies have suggested a causal relationship
between the inﬂammatory responses to the durable polymer
and VLST, provoking late ISA and accelerated atherosclerosis
followed by neointimal disruption. Histopathologic diﬀer-
ences (the prevalence of eosinophils, giant cells, and ﬁbrin)
among DES platforms have been observed; this may reﬂect
unique responses to the speciﬁc polymer/drug.
Thus, until novel DES using superbly biocompatible
and/or biodegradable polymers becomes available, we still
need to be cautious and carefully keep surveying these
devices.
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